Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O00358
UPID:
FOXE1_HUMAN
Alternative names:
Forkhead box protein E2; Forkhead-related protein FKHL15; HFKH4; HNF-3/fork head-like protein 5; Thyroid transcription factor 2
Alternative UPACC:
O00358; O75765; Q5T109; Q99526
Background:
Forkhead box protein E1, also known as Forkhead box protein E2 and Thyroid transcription factor 2, plays a pivotal role in transcription regulation, palate formation, and thyroid gland morphogenesis. It activates gene promoters, including MSX1 and TGFB3, essential for developmental processes.
Therapeutic significance:
Linked to Bamforth-Lazarus syndrome and non-medullary thyroid cancer, Forkhead box protein E1's understanding could pave the way for innovative treatments targeting these conditions through gene regulation and developmental pathway modulation.